$KYTX News

Kyverna Therapeutics to Present at Upcoming Investor Conferences

Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results

Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate

Kyverna Therapeutics: 'Strong Buy' On ElevateBio Manufacturing Deal And RA Program Advancement

Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel

Kyverna Therapeutics shares are trading higher after the company and ElevateBio announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel, autologous CD19-directed CAR T-cell therapy.

Kyverna Therapeutics, ElevateBio Announce Manufacturing Agreement For Both U.S. Commercial And Global Clinical Supply Of Miv-Cel, Kyverna’s Autologous CD19-Directed CAR T-Cell Therapy

Kyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and Beyond

Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

Kyverna Therapeutics, Inc. (KYTX) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow

HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price Target

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Kyverna Therapeutics Reports Phase 1 Data For Miv-Cel In Rheumatoid Arthritis, Showing Deep B-Cell Depletion And Potential Immune Reset At Week 36

Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

KYV-101 Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $25

Kyverna Therapeutics to Present at Upcoming Investor Conferences

JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29